In preterm infants with necrotizing enterocolitis, when should ceftazidime‑avibactam and aztreonam be used, and what are the appropriate dosing and safety considerations?

Ceftazidime-Avibactam and Aztreonam in Preterm Infants with Necrotizing Enterocolitis

For preterm infants with necrotizing enterocolitis (NEC), ceftazidime-avibactam and aztreonam are NOT standard first-line agents and should only be used when multidrug-resistant (MDR) or carbapenem-resistant Gram-negative organisms are documented or strongly suspected based on local epidemiology.

When to Use These Agents

Standard NEC Treatment

For typical NEC management, the established guideline-recommended regimens are 1:

• Ampicillin + gentamicin + metronidazole
• Ampicillin + cefotaxime + metronidazole
• Meropenem (as monotherapy alternative)

These cover the expected polymicrobial flora (Gram-negatives, anaerobes, and Gram-positives including enterococci).

Reserved Indications for CAZ-AVI ± Aztreonam

Use ceftazidime-avibactam when:

• Cultures grow carbapenem-resistant Enterobacterales (CRE) producing KPC or OXA-48-like carbapenemases
• MDR Pseudomonas aeruginosa resistant to standard agents but susceptible to CAZ-AVI
• Prior antibiotic failure with documented resistant organisms

Add aztreonam to ceftazidime-avibactam when:

• Metallo-β-lactamase (MBL) producers are identified (NDM, VIM, IMP) 2, 3
• The combination provides synergistic activity against MBL-producing organisms since aztreonam is not hydrolyzed by MBLs while avibactam protects it from other β-lactamases

Dosing Recommendations

Ceftazidime-Avibactam Dosing in Preterm Infants

Based on FDA labeling and emerging neonatal data 4, 5, 6:

For infants ≤28 days postnatal age with gestational age ≥31 weeks:

• 25 mg/kg every 8 hours (based on ceftazidime component: 20 mg/kg ceftazidime + 5 mg/kg avibactam)
• Infuse over 2 hours

For infants >28 days to <3 months:

• 37.5 mg/kg every 8 hours (30 mg/kg ceftazidime + 7.5 mg/kg avibactam)
• Infuse over 2 hours

Critical considerations:

• These doses assume normal renal function
• Monitor renal function closely; dosing adjustments needed if creatinine clearance declines
• Insufficient data exist for preterm infants <31 weeks gestational age or those with renal impairment 4
• Target pharmacodynamic goal: %fT>MIC ≥70% 6

Aztreonam Dosing

When combined with CAZ-AVI for MBL producers 1:

Neonates:

• 90-120 mg/kg/day divided every 6-8 hours
• Standard dosing: 30 mg/kg every 8 hours IV

Duration:

• Typical course: 10-14 days for complicated intra-abdominal infections including NEC with perforation 1
• May extend based on clinical response and source control adequacy

Safety Considerations

Monitoring Requirements

• Renal function: Check serum creatinine at baseline and monitor closely (at least every 2-3 days) 4, 5
• Liver function: Transaminases may elevate; monitor weekly 5, 7
• Electrolytes: Watch for hypomagnesemia (reported adverse effect) 5
• Hematologic: Monitor for thrombocytopenia 5

Known Adverse Effects in Neonates

From case series 5, 7:

• Reversible liver enzyme elevations (most common)
• Increased serum creatinine (usually mild and reversible)
• Hypomagnesemia
• Thrombocytopenia
• CNS concerns: One case report noted status epilepticus in a preterm infant, though causality uncertain 5

Critical Pitfalls to Avoid

1. Do not use empirically without microbiological justification—these are last-resort agents
2. Do not underdose: Preterm infants have increased volume of distribution; weight-based dosing is essential 6, 8
3. Do not forget source control: Surgical intervention (laparotomy, drainage) remains paramount in NEC with perforation 1, 9
4. Do not use CAZ-AVI alone for MBL producers: It will fail; aztreonam must be added 2, 3
5. Do not overlook anaerobic coverage: Continue metronidazole concurrently for NEC 1, 4

Clinical Algorithm for Decision-Making

Step 1: Initiate standard NEC regimen (ampicillin + gentamicin + metronidazole)

Step 2: Obtain cultures (blood, peritoneal fluid if surgery performed)

Step 3: If clinical deterioration despite 48-72 hours of therapy:

• Review culture results and susceptibilities
• Consider local antibiogram for resistant organisms

Step 4: Switch to CAZ-AVI ± aztreonam if:

• CRE or MDR Pseudomonas documented
• MBL producer identified → must add aztreonam
• KPC or OXA-48 producer → CAZ-AVI alone acceptable

Step 5: Ensure adequate source control (surgical drainage/resection)

Step 6: Monitor response:

• Clinical improvement expected within 48-72 hours 5, 9, 7
• Repeat cultures should clear within 48-72 hours of appropriate therapy
• Continue monitoring renal/hepatic function throughout treatment

Evidence Quality Note

The evidence for CAZ-AVI use in preterm infants with NEC is very limited, consisting primarily of case reports and small case series 5, 6, 9, 7. The FDA labeling provides dosing for infants ≥31 weeks gestational age 4, but pharmacokinetic data in extremely preterm infants remain insufficient. The combination with aztreonam for MBL producers is supported by moderate-quality evidence in older populations 2, 3 but extrapolated to neonates based on mechanism of action and limited case experience 9.